<DOC>
	<DOCNO>NCT01261312</DOCNO>
	<brief_summary>Phase 1-2 dose escalation randomize study patient intermediate high risk myelodysplastic syndrome ( MDS ) acute myelogenous leukemia ( AML ) . The Dose Escalation Segment evaluate biological activity , preliminary safety efficacy SGI-110 two dose schedule MDS AML patient Dose Expansion Segment evaluate safety efficacy biological effective dose ( BED ) maximum tolerate dose ( MTD ) define Dose Escalation Segment .</brief_summary>
	<brief_title>SGI-110 Patients With Myelodysplastic Syndromes ( MDS ) Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>Once BED MTD determine Dose Escalation Segment , Dose Expansion Segment randomize patient MDS , treatment naïve elderly AML , relapsed/refractory AML patient receive BED MTD dose . Relapsed/refractory AML patient may also receive SGI-110 daily x 10 schedule base total dose per cycle evaluate Dose Escalation Segment use 5-daily regimen .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Men woman , 18 year age old , confirm diagnosis international prognostic scoring system ( IPSS ) intermediate1 , intermediate2 highrisk MDS include Chronic Myelomonocytic Leukemia ( CMML ) AML . In Dose Escalation Segment , patient refractory , relapse , unresponsive standard treatment . In Dose Expansion Segment , hypomethylating agent ( HMA ) treatmentnaïve MDS subject ( include CMML ) , intermediate2 highrisk MDS subject ( include CMML ) relapse refractory prior HMA treatment allow , treatmentnaïve AML subject least 65 year age allow also least one follow criterion AML secondary MDS , chemotherapy , radiation therapy poor cytogenetics preexist clinically significant dysfunction heart Chronic Obstructive Pulmonary Disease ( COPD ) poor performance status , Eastern Cooperative Oncology Group ( ECOG ) , 2 2 . Eastern ECOG performance status 0 2 . 3 . Adequate organ function . 4 . Prior allogeneic stem cell transplant , evidence active graftversus host disease ( GVHD ) must ≥ 2 week immunosuppressive therapy . 5 . No major surgery within 4 week first dose SGI110 . 6 . No chemotherapy within 2 week first dose SGI110 ( minimum 6 week nitrosoureas 8 week bone marrow transplantation ) exception hydroxyurea allow course 1 treatment . 7 . Sign approve informed consent form study . 1 . In Dose Expansion Segment , include 10day regimen , subject receive 2 complete full dose cycle hypomethylating agent ( HMA ) decitabine azacitidine ( except intermediate2 highrisk MDS subject ( include CMML ) relapse refractory prior HMA treatment ) . 2 . Acute promyelocytic leukemia ( M3 classification ) . 3 . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free least 3 year . 4 . Lifethreatening illness AML MDS , uncontrolled medical condition organ system dysfunction , investigator 's opinion , could compromise patient 's safety , put study outcome risk . 5 . Known history human immunodeficiency virus ( HIV ) active infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) . 6 . Hypersensitivity decitabine , SGI110 , SGI110 excipients . 7 . With exception treatmentnaïve elderly AML patient , patient uncontrolled congestive heart failure ( CHF ) , coronary heart disease ( CAD ) , chronic obstructive pulmonary disease ( COPD ) , leave ventricular ejection fraction ( LVEF ) ≤ 50 % exclude , symptomatic uncontrolled arrhythmias continuous corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SGI-110</keyword>
	<keyword>DNA Hypomethylating Agent</keyword>
	<keyword>Intermediate 1 , Intermediate 2 , CMML High Risk MDS</keyword>
	<keyword>AML</keyword>
</DOC>